Open access
Sep 2026
Risk Stratification and Factors Associated with Heart Failure Hospitalization During Osimertinib Therapy
Background: Osimertinib is the standard of care for epidermal growth factor receptor mutation-positive non-small cell lung cancer, but heart failure hospitalization (HFH) remains a concern, and no practical tool exists to stratify HFH risk during therapy. Methods: In this retrospective cohort study using a Japanese cla...
T. Sugimoto, Yoshihiro Noguchi, Rikuto Masuda et al.
· Current Oncology · 0 citations